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Abstract
We report on two cases of women on trastuzumab therapy for breast cancer who became
pregnant and delivered healthy live infants. At the time of reporting the children are growing and
developing normally (ages 3 and 2).
Background
Trastuzumab (Herceptin®) is a monoclonal IgG1 antibody
to the human epidermal growth factor HER2/neu receptor
which is indicated in the treatment of breast cancers over-
expressing the HER2 receptor. Although in preclinical
studies placental transfer occurred in monkeys, trastuzu-
mab has not been directly shown to cross the human pla-
centa. However placental transfer of IgG1 is documented
[1] and has been shown for other IgG1 antibodies rituxi-
mab[2] and infliximab[3]. There is little information in
the literature regarding the safe use of trastuzumab in
pregnancy, although some reports suggest an increased
risk of oligohydramnios during the second and third tri-
mesters[4,5], and the drug carries a United States Food
and Drug Administration category D warning label (there
is positive evidence of human fetal risk, but the benefits
from use in pregnant women may be acceptable despite
the risk) [6].
Case Presentation 1
A 30 year old female was diagnosed with a locally
advanced right breast cancer for which she received neo-
adjuvant chemotherapy with doxorubicin and cyclophos-
phamide followed by docetaxel. She then proceeded to
mastectomy and axillary node clearance for node positive,
hormone receptor negative disease, followed by adjuvant
radiotherapy. Subsequently, she underwent left mastec-
tomy.
She conceived whilst clinically disease-free and had an
uneventful first trimester. During the second trimester she
presented with right-sided rib pain and a malignant pleu-
ral effusion. HER2/neu receptor studies on the primary
tumor at the time of relapse were positive, and she was
commenced on single agent trastuzumab.
At 29 weeks gestation, she gave birth to a live female
weighing 1220 g by elective caesarean section. She did not
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breast-feed. The infant's postnatal period was complicated
by respiratory distress syndrome, and concern about con-
ductive hearing loss, which subsequently resolved.
During ongoing paediatric follow-up, the baby was noted
to have mild hypertonia and hyperreflexia, which subse-
quently resolved, and minimal tightening of her left
Achilles tendon. At the current age of 3, the child is cogni-
tively normal with height at the 50th percentile, and
weight and head circumference at the 25th centile. She
has ongoing minimal tightness of her left Achilles tendon,
but no obvious neurological deficit.
Case Presentation 2
A 36 year old female was diagnosed with locally advanced
cancer of the right breast, for which she underwent total
mastectomy and axillary clearance. The tumour was hor-
mone receptor negative and HER2 receptor positive.
She received adjuvant doxorubicin and cyclophospha-
mide followed by docetaxel, as well as chest wall and
regional radiation.
She was subsequently enrolled in the Herceptin® Adjuvant
(HERA) trial, which compared adjuvant trastuzumab to
observation in women with HER2-positive primary breast
cancer who had completed adjuvant chemotherapy [7].
She was initially randomised to the observation control
arm, but was later offered trastuzumab treatment after the
preliminary results of the HERA study were reported (as
permitted by a change in the study protocol).
The patient was found to be 6 weeks pregnant, at which
stage she had received 6 doses of trastuzumab. No further
trastuzumab was administered. The patient had had 3 pre-
vious pregnancies, 2 of which had resulted in spontane-
ous abortions.
Two gestational sacs were shown on initial ultrasound
imaging, with only one sac showing a live fetus, a finding
confirmed on subsequent scans. The patient elected to
continue the pregnancy which was otherwise uncompli-
cated. At 39 weeks gestation a healthy female infant (birth
weight 2.94 kg) was born by normal vaginal delivery.
The baby was formula fed. The infant was admitted for
gastroenteritis at the age of 3, 8 and 11 months of age, but
recovered well from each episode. Subsequent growth and
development have been normal with the child now aged
2.
Discussion
Breast cancer is relatively uncommon in pregnancy, with
up to 1/3000 live births affected. Cancers tend to be more
aggressive and advanced at presentation, with a resultant
poorer prognosis. They are also often associated with
other poor prognostic factors such as lymphovascular
invasion, hormone insensitivity, and over-expression of
HER2/neu. As a class of chemotherapeutic drugs, anthra-
cyclines have the largest safety data in pregnancy, with a
low rate of congenital malformations, mostly occurring in
the setting of first-trimester exposure [8].
Only 8 case reports currently exist in the literature with
regards to the use of trastuzumab in pregnancy (Table 1).
Watson described a case of anhydramnios occurring at 23
weeks' gestation during adjuvant trastuzumab treatment
commenced pre-conception. This resolved slowly after
drug cessation [5].
Fanale et al reported on a patient with metastatic breast
cancer treated with combination vinorelbine and trastu-
zumab, with good disease response, and a healthy male
infant born at 34 weeks gestation [9].
Waterston and Graham described a patient receiving adju-
vant trastuzumab, who conceived while on treatment. At
the time of confirmation of pregnancy in the first trimes-
ter, the patient had already received 3 cycles of trastuzu-
mab. The drug was stopped, and a normal pregnancy and
birth ensured, with a healthy female delivered and no
long-term sequelae reported [10].
Bader et al reported on a patient treated at 26 and 29
weeks gestation with trastuzumab and paclitaxel for met-
astatic breast cancer presenting during pregnancy. The
fetus developed anhydramnios due to renal failure. A
male infant was born at 32 weeks by elective caesarean
section. Serum creatinine was mildly elevated and ultra-
sound of kidneys showed transient hyperechodensities,
but these abnormalities resolved, and a healthy infant was
discharged at age 6 weeks. Development was normal at 12
weeks [4].
Shrim et al described a patient on maintenance single-
agent trastuzumab for metastatic breast cancer who unex-
pectedly conceived. Trastuzumab was continued until 24
weeks gestation, when it was stopped for asymptomatic
persistent mildly reduced ejection fraction. The pregnancy
was otherwise uneventful. A healthy female was born at
37 weeks gestation by caesarean section (performed due
to breech presentation), with ensuing normal growth and
development noted in the short-term [11].
Sekar and Stone reported on a lady who presented at 20
weeks gestation with metastatic breast cancer and received
docetaxel and trastuzumab. An ultrasound 4 weeks after 2
cycles of chemotherapy revealed anhydramnios. A follow-
up ultrasound 7 weeks post chemotherapy showed reap-
pearance of amniotic fluid [12].C
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Table 1: Trastuzumab use during pregnancy
Case 1 Case 2 Watson5 Fanale9 Waterston10 Bader4 Shrim11 Sekar12 Witzel13 Pant14
Maternal age 33 38 28 29 30 38 32 28 ~32 ~33
Stage IV III II IV II IV IV IV IV IV
Treatment T T T T/V T T/P T T/D T T
Initiation 2nd trimester Pre Pre 27/40 Pre 25/40 Pre 23/40 Pre Pre
Completion 29/40 6/40 20/40 34/40 1/40 28/40 24/40 27/40 NS 30/40
Antenatal 
complications
None 1 of 2 viable fetal 
sacs
None Oligo None Anhydramnios
"Renal failure"
None Anhydramnios Oligo, Vaginal 
Bleeding
Oligo
Delivery CS VD VD VD VD CS CS CS CS VD
Gestation 29 39 37.5 34+5 Term 32+1 37 36+2 28 32+1
Perinatal Comp. Nil Nil Nil Nil Nil Fetal distress Breech Breech Bleeding Nil
S e xF F F M F MF MF F
Birthweight 1220 g 2940 g 2960 g 2270 g NS 1460 g 2600 g 2230 g 1015 g 1810 g
Neonatal RDS Normal Normal Normal NS Sepsis, RDS RDS Normal Multiorgan Failure Normal
Outcome Nil significant Normal Normal Normal NS Normal Normal Normal Neonatal death Normal
Duration of 
follow-up
3 years 2 years 6/12 6/12 NS 3/12 2/12 NS 21 weeks 60/12
T = Trastuzumab, V = Vinorelbine, P = Paclitaxel, D = Docetaxel, Pre = Pre-pregnancy, NS = Not stated, Oligo = Oligohydramnios, CS = Caesarean section, VD = Vaginal Delivery, RDS = 
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Witzel and Müller described a patient with metastatic
breast cancer, treated with trastuzumab and vinorelbine
with disease remission followed by maintenance trastuzu-
mab. The woman conceived while on maintenance ther-
apy. At 27 weeks gestation, the patient presented with
oligohydramnios and vaginal bleeding. Caesarean section
was subsequently performed for ongoing bleeding. The
newborn infant developed respiratory failure, capillary
leak syndrome, persisting infections and necrotizing ente-
rocolitis, and ultimately died [13].
Finally, Pant et al reported on a patient treated with pacl-
itaxel and trastuzumab for metastatic breast cancer with
excellent disease response, and subsequent maintenance
trastuzumab. She was unexpectedly found to be pregnant
at 14 weeks gestation, but elected to continue receiving
treatment. After several weeks of low normal amniotic
fluid volume, the patient developed oligohydramnios at
32 weeks gestation and a caesarean section was per-
formed. A healthy child was born with no immediate or
longer term (up to 5 years of age) sequelae noted [14].
A mechanism proposed for the association between tras-
tuzumab use in the expectant mother and the develop-
ment of oligohydramnios is that epidermal growth factor
receptors are expressed in the fetal kidney during develop-
ment, inducing DNA synthesis and mitosis, and that
blocking these receptors, such as might occur with trastu-
zumab, leads to a decrease in kidney cell proliferation [1].
Conclusion
Although information regarding the safety of trastuzumab
for breast cancer during pregnancy is scant, there appears
to be an increased incidence of oligohydramnios associ-
ated with the use of the agent. This was reversible on dis-
continuation of the drug in most cases. Trastuzumab was
associated with neonatal death in one instance. Despite
this, the majority of infants did not appear to have suf-
fered significant long-term sequelae resulting from the use
of the agent and its benefit in disease control warrants
consideration of use during pregnancy (particularly
beyond the first trimester) with careful monitoring of fetal
well-being (including amniotic fluid volume).
Patient's Perspective
"My daughter is now 3 1/2 years and is perfectly normal.
I would have no problem recommending Herceptin dur-
ing pregnancy. If any concerned patient would like to con-
tact me and see my daughter I would be glad to put their
mind at ease."
Consent
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available for review from the journal's Editor-in-Chief.
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